LONDON - On Wednesday, GlaxoSmithKline plc (NYSE: NYSE:GSK ... below the £0.49 analysts were expecting. The company's top-line performance was driven by continued growth in its Specialty ...

Learn more about whether Corcept Therapeutics Incorporated or GSK plc is a better investment based on AAII's A+ Investor ...

CEO Emma Walmsley said the company has been anticipating tariffs on the industry and is “confident” the company can navigate through it, Ashleigh Furlong and Ruth David of Bloomberg reports. The U.S.

NEW YORK CITY, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

GSK PLC closed 26.98% short of its 52-week high of £18.24, which the company reached on May 16th.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK ...

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together. The Company is ...

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a global healthcare company dedicated to leveraging science, technology, and talent to address disease challenges worldwide.

DUBLIN--(BUSINESS WIRE)--The "Enterprise Tech Ecosystem Series: GSK plc 2024" company profile has been added to ResearchAndMarkets.com's offering. The report provides insights into company's tech ...

GSK PLC closed 30.68% below its 52-week high of £18.24, which the company achieved on May 16th.